Absci Corporation

Absci is a generative AI drug creation company that combines AI with scalable wet lab capabilities to design novel biologic drugs from scratch. The company's Integrated Drug Creation platform enables de novo design of therapeutic antibodies, moving from target to clinical-ready candidates faster than traditional methods. Absci has established major partnerships with AstraZeneca and Almirall, validating its AI-first approach to biologics discovery.

Partnered programs with AstraZeneca (oncology) and Almirall (dermatology)

Integrated Drug Creation platform combining generative AI for de novo antibody design with scalable wet lab validation. The platform designs functional antibodies against difficult-to-drug targets and validates them experimentally in a closed-loop system.